Skip to main content
PMC home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1984 Oct 6;289(6449):858–859. doi: 10.1136/bmj.289.6449.858

Oral gold for rheumatoid arthritis.

V Wright
PMCID: PMC1443414  PMID: 6434113

Full text

PDF
858

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernhard G. C. Auranofin treatment for adult rheumatoid arthritis. Comparison of 2 mg and 6 mg daily dose. J Rheumatol Suppl. 1982 Jul-Aug;8:149–153. [PubMed] [Google Scholar]
  2. Bird H. A., Le Gallez P., Dixon J. S., Surrall K. E., Cole D. S., Goldman M. H., Wright V. A single-blind comparative study of auranofin and hydroxychloroquine in patients with rheumatoid arthritis. Clin Rheumatol. 1984 Mar;3 (Suppl 1):57–66. doi: 10.1007/BF03342623. [DOI] [PubMed] [Google Scholar]
  3. Blodgett R. C., Jr, Heuer M. A., Pietrusko R. G. Auranofin: a unique oral chrysotherapeutic agent. Semin Arthritis Rheum. 1984 Feb;13(3):255–273. doi: 10.1016/0049-0172(84)90029-5. [DOI] [PubMed] [Google Scholar]
  4. Calin A., Saunders D., Bennett R., Jacox R., Kaplan D., O'Brien W., Paulus H. E., Roth S., Weiss T. Auranofin: 1 mg or 9 mg? The search for the appropriate dose. J Rheumatol Suppl. 1982 Jul-Aug;8:146–148. [PubMed] [Google Scholar]
  5. Dequeker J., Verdickt W., Gevers G., Vanschoubroek K. Longterm experience with oral gold in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol. 1984 Mar;3 (Suppl 1):67–74. doi: 10.1007/BF03342624. [DOI] [PubMed] [Google Scholar]
  6. Dimartino M. J., Walz D. T. Inhibition of lysosomal enzyme release from rat leukocytes by auranofin. A new chrysotherapeutic agent. Inflammation. 1977 Jun;2(2):131–142. doi: 10.1007/BF00918675. [DOI] [PubMed] [Google Scholar]
  7. Dixon J. S., Pickup M. E., Bird H. A., Lee M. R., Wright V., Downie W. W. Biochemical indices of response to hydroxychloroquine and sodium aurothiomalate in rheumatoid arthritis. Ann Rheum Dis. 1981 Oct;40(5):480–488. doi: 10.1136/ard.40.5.480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dorwart B. B., Gall E. P., Schumacher H. R., Krauser R. E. Chrysotherapy in psoriatic arthritis. Efficacy and toxicity compared to rheumatoid arthritis. Arthritis Rheum. 1978 Jun;21(5):513–515. doi: 10.1002/art.1780210504. [DOI] [PubMed] [Google Scholar]
  9. Furst D. E., Dromgoole S. H. Comparative pharmacokinetics of triethylphosphine gold (auranofin) and gold sodium thiomalate (GST). Clin Rheumatol. 1984 Mar;3 (Suppl 1):17–24. doi: 10.1007/BF03342618. [DOI] [PubMed] [Google Scholar]
  10. Girdwood R. H. Death after taking medicaments. Br Med J. 1974 Mar 16;1(5906):501–504. doi: 10.1136/bmj.1.5906.501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gottlieb N. L., Smith P. M., Smith E. M. Pharmacodynamics of 197Au and 195Au labeled aurothiomalate in blood. Correlation with course of rheumatoid arthritis, gold toxicity and gold excretion. Arthritis Rheum. 1974 Mar-Apr;17(2):171–183. doi: 10.1002/art.1780170211. [DOI] [PubMed] [Google Scholar]
  12. Griffin A. J., Gibson T., Huston G., Taylor A. Maintenance chrysotherapy in rheumatoid arthritis: a comparison of 2 dose schedules. Ann Rheum Dis. 1981 Jun;40(3):250–253. doi: 10.1136/ard.40.3.250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Husby G., Gran J. T. Risk factors in the treatment of rheumatoid arthritis with parenteral gold. Scand J Rheumatol Suppl. 1983;51:112–115. doi: 10.3109/03009748309095362. [DOI] [PubMed] [Google Scholar]
  14. Jellum E., Aaseth J., Munthe E. Is the mechanism of action during treatment of rheumatoid arthritis with penicillamine and gold thiomalate the same? Proc R Soc Med. 1977;70 (Suppl 3):136–139. [PMC free article] [PubMed] [Google Scholar]
  15. Lewis D., Capell H. A. Oral gold: a comparison with placebo and with intramuscular sodium aurothiomalate. Clin Rheumatol. 1984 Mar;3 (Suppl 1):83–96. doi: 10.1007/BF03342626. [DOI] [PubMed] [Google Scholar]
  16. McConkey B., Crockson R. A., Crockson A. P. The assessment of rheumatoid arthritis. A study based on measurements of the serum acute-phase reactants. Q J Med. 1972 Apr;41(162):115–125. [PubMed] [Google Scholar]
  17. McKenzie J. M. Report on a double-blind trial comparing small and large doses of gold in the treatment of rheumatoid disease. Rheumatol Rehabil. 1981 Nov;20(4):198–202. doi: 10.1093/rheumatology/20.4.198. [DOI] [PubMed] [Google Scholar]
  18. Panayi G. S., Wooley P., Batchelor J. R. Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs. Br Med J. 1978 Nov 11;2(6148):1326–1328. doi: 10.1136/bmj.2.6148.1326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rothermich N. O., Philips V. K., Bergen W., Thomas M. H. Chrysotherapy. A prospective study. Arthritis Rheum. 1976 Nov-Dec;19(6):1321–1327. doi: 10.1002/art.1780190613. [DOI] [PubMed] [Google Scholar]
  20. Sharp J. T., Lidsky M. D., Duffy J., Thompson H. K., Jr, Person B. D., Masri A. F., Andrianakos A. A. Comparison of two dosage schedules of gold salts in the treatment of rheumatoid arthritis. Relationship of serum gold levels to therapeutic response. Arthritis Rheum. 1977 Jul-Aug;20(6):1179–1187. doi: 10.1002/art.1780200604. [DOI] [PubMed] [Google Scholar]
  21. Sigler J. W., Bluhm G. B., Duncan H., Sharp J. T., Ensign D. C., McCrum W. R. Gold salts in the treatment of rheumatoid arthritis. A double-blind study. Ann Intern Med. 1974 Jan;80(1):21–26. doi: 10.7326/0003-4819-80-1-21. [DOI] [PubMed] [Google Scholar]
  22. Ward J. R., Williams H. J., Egger M. J., Reading J. C., Boyce E., Altz-Smith M., Samuelson C. O., Jr, Willkens R. F., Solsky M. A., Hayes S. P. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 1983 Nov;26(11):1303–1315. doi: 10.1002/art.1780261102. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES